Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
British pharmaceutical giant GSK plc (LON:GSK) is reportedly in advanced negotiations to acquire U.S.-based cancer drug developer Nuvalent Inc. (NASDAQ: NUVL) in a deal that could be worth more than $9 billion, according to a report published by the Financial Times on Tuesday.
Sources familiar with the matter said both companies are working toward finalizing an agreement as early as this week. However, discussions remain ongoing, and there is still a possibility that the deal could fall through if last-minute challenges arise.
If completed, the proposed acquisition would value Massachusetts-headquartered Nuvalent between $9 billion and $10 billion. The valuation represents a substantial premium over Nuvalent’s market capitalization, which stood at nearly $7 billion at the close of trading on Monday.
The potential takeover would mark GSK’s largest acquisition in more than a decade and rank among the most significant transactions in the company’s history. The move aligns with CEO Luke Miels’ strategy to expand and strengthen GSK’s oncology portfolio as the pharmaceutical industry increasingly focuses on innovative cancer treatments.
Nuvalent has gained attention for its work in developing targeted cancer therapies designed to address resistance mechanisms in tumors. Its lead drug candidate, neladalkib, is being developed for the treatment of lung cancer and is currently under review by U.S. regulators. Approval of the therapy could significantly enhance Nuvalent’s value and commercial prospects.
The reported deal comes during a period of heightened activity in the global biotechnology sector. According to Dealogic data cited in the report, biotech and pharmaceutical mergers and acquisitions have reached nearly $211 billion in announced transactions so far this year, highlighting strong demand for promising drug-development companies.
Should the acquisition move forward, it would further reinforce GSK’s commitment to cancer research and provide the company with valuable assets in the rapidly growing oncology market.
